logo-loader
Silence Therapeutics PLC

Silence Therapeutics Publication of Annual Report

/**/ h1{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:9.85pt;margin-bottom:.0001pt;text-align:justify;text-autospace:none;font-size:12.0pt;font-family:"Calibri","sans-serif";font-weight:bold;}h2{margin-top:.05pt;margin-right:0cm;margin-bottom:0cm;margin-left:5.85pt;margin-bottom:.0001pt;text-align:justify;text-autospace:none;font-size:12.0pt;font-family:"Calibri Light","sans-serif";font-weight:normal;}h3{margin-top:0cm;margin-right:0cm;margin-bottom:0cm;margin-left:5.85pt;margin-bottom:.0001pt;text-align:justify;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:11.0pt;font-family:"Calibri","sans-serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: #0563C1 }visited{ color: #954F72 } .aa{size:595.0pt 842.5pt;margin:68.05pt 62.35pt 2.0cm 62.35pt;}div.aa{}p.bd{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-right:2.5pt}span.bb{font-size:16.0pt;font-family:"Calibri Light","sans-serif";color:#234060}span.az{font-size:15.0pt;font-family:"Calibri Light","sans-serif";color:#234060}p.be{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify}p.bf{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";text-align:justify;line-height:112%}span.ax{color:#171717}span.av{font-size:10.0pt; line-height:112%;font-family:"Arial","sans-serif";color:black}p.bg{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-top: .4pt} span.au{color:black}p.bh{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-left: 5.85pt; text-align: justify}p.bi{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:.4pt;margin-right:0cm;margin-bottom:0cm; margin-left:5.85pt;margin-bottom:.0001pt}span.ar{font-size:10.0pt; color:black}table.bj{width:460.7pt;margin-left:3.4pt;border-collapse:collapse}tr.al{height:34.15pt}td.an{width:312.5pt;padding:0cm 5.4pt 0cm 5.4pt; height:34.15pt}p.bk{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; margin-bottom: 0cm; margin-left: 5.85pt; margin-right: 4.75pt; margin-top: 0cm; text-align: justify}p.bl{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:0cm;margin-right:4.75pt;margin-bottom: 0cm;margin-left:5.85pt;margin-bottom:.0001pt;text-align:justify}td.am{width:126.6pt;padding:0cm 5.4pt 0cm 5.4pt; height:34.15pt} tr.ah{height:26.15pt}td.aj{width:312.5pt;padding:0cm 5.4pt 0cm 5.4pt; height:26.15pt}p.bm{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-left:5.85pt}td.ai{width:126.6pt;padding:0cm 5.4pt 0cm 5.4pt; height:26.15pt}td.ag{width:312.5pt;padding:0cm 5.4pt 0cm 5.4pt}td.af{width:126.6pt;padding:0cm 5.4pt 0cm 5.4pt}p.bn{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";margin-top:.4pt}span.ad{font-size: 10.0pt;font-family:"Arial","sans-serif"}p.bo{margin:0cm;margin-bottom:.0001pt;text-autospace:none;font-size:11.0pt;font-family:"Calibri","sans-serif";font-weight: bold; text-align: justify} /**/
RNS Number : 5503W
Silence Therapeutics PLC
18 April 2019
 

Silence Therapeutics Notice of Annual General Meeting and publication of Annual Report

 

April 18, 2019

 

LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that its annual report and financial statements for the year ended 31 December 2018 ("Annual Report and Accounts") is available for download on the Company's website www.silence-therapeutics.com. The Annual Report and Accounts will be posted to shareholders on or before 21 May 2019.

 

This year's Annual General Meeting ("AGM") of the Company will be held on 25 June 2019 at 10am. The Notice of the AGM will be posted to shareholders on or before 21 May 2019, when it will also be made available on the Company's website. The AGM will be held at the offices of Silence Therapeutics Plc, 72 Hammersmith Road, London, United Kingdom W14 8TH, and registration of attendees and the distribution of voting slips will commence at the meeting venue at 9.45am.  

 

 

 

Enquiries:

 

Silence Therapeutics plc

Dr David Horn Solomon, Chief Executive Officer

 

Tel:  +44 (0)20 3457 6900

Peel Hunt LLP (Nominated Adviser and Broker)

James Steel/Oliver Jackson

 

Tel:  +44 (0)20 7418 8900

European IR

Consilium Strategic Communications

Mary-Jane Elliott/Chris Welsh/Angela Gray

[email protected]

 

Tel: +44 (0) 20 3709 5700

US IR

Westwicke Partners

Peter Vozzo

[email protected]

 

 Tel: +1 (443) 213-0505

 

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural

mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively

inhibit any gene in the genome, specifically silencing the production of disease-causing proteins. Using

its enabling delivery systems, it has achieved an additional level of specificity by delivering its

therapeutic RNA molecules exclusively to target cells. Silence's proprietary RNA chemistries and

delivery systems are designed to improve the stability of our molecules and enhance effective delivery

to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases.

For more information, please visit: https://www.silence-therapeutics.com/ 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCEAKLXFFNNEFF

Quick facts: Silence Therapeutics PLC

Price: £2.06

Market: AIM
Market Cap: £160.5 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Silence Therapeutics hails 'transformational' deal with US firm Mallinckrodt

Silence Therapeutics PLC's (LON:SLN) David Solomon discusses the partnership they've struck with US biopharmaceutical firm Mallinckrodt PLC (NYSE: MNK) to develop and commercialise gene silencing treatments for serious diseases. Mallinckrodt will obtain an exclusive worldwide license to...

on 22/7/19

RNS

Additional Listing

1 day, 9 hours ago

Additional Listing

3 days, 4 hours ago

Additional Listing

1 week, 2 days ago

Additional Listing

2 weeks ago

Additional Listing

2 weeks, 1 day ago

Additional Listing

2 weeks, 2 days ago